AAPS PharmSciTech ( # 2013)DOI: 10.1208/s12249-013-9989-2
Polydimethylsiloxane–Indomethacin Blends and Nanoparticles
Received 12 February 2013; accepted 28 May 2013
Abstract. A series of blends of polydimethylsiloxane (PDMS) and indomethacin (IMC), containing 20–80 wt.% IMC were obtained and characterized by differential scanning calorimetry, Fourier transform–infraredspectroscopy, and powder X-ray diffraction in order to observe the mutual influence of the two components.
The main thermal transitions of PDMS remained un-changed. Both the solvent (tetrahydrofuran, THF) andthe PDMS influenced the crystalline form of IMC. The blends were subsequently re-dissolved in THF, with orwithout cross-linking reagents added and precipitated into diluted aqueous solutions of siloxane-based surfac-tants. The resulted nanoparticles were analyzed by dynamic light scattering and scanning electron microscopy.
Most of the particles had diameters between 200 and 300 nm. The surfactants, the IMC content and the cross-linking influenced the particles size and polydispersity, as well as the nanoparticle yield. The maximum drugrelease from selected aqueous formulations was 30%.
KEY WORDS: indomethacin; nanoparticles; polydimethylsiloxane.
The anti-inflammatory non-steroidal drugs (AINS) are used
in rheumatoid and osteoarthritis and in local inflammation (11).
Polysiloxanes have many biomedical uses, especially in
The oral therapy with AINS is very efficient, but the clinical use is
implantology, transdermic applications and drug delivery (1–3).
often limited due to potential side effects, like irritations and
They are well-known for their biocompatibility (especially refer-
ulcerations of the gastro-intestinal mucous membrane (12). These
ring to high molecular weight homologs) and at the same time,
well-known side effects of AINS oral administration acceler-
they are among the most tested materials concerning safety
ated the development of alternative pharmaceutical formula-
(2,4,5). Apart the biological inertness, polysiloxanes are charac-
tions, such as creams, gels, and topic foams, which allow the
terized by hydrophobicity, permeability to diffusion of different
local adsorption to the inflammation site, without adverse sys-
substances, including gases, water vapors and drugs, as well as by
temic reactions (13). Nevertheless, effective drug encapsulationfor oral or parenteral use is very important for limiting side
specific visco-elastic properties (2). The controlled release of
effects and maintaining efficiency. Indomethacin (IMC) is a
active drugs with polydimethylsiloxane (PDMS) goes back to
hydrophobic, model AINS drug in many investigations.
the 1960s (6). At the present, there are numerous commercially
Different applications have been proposed for drug-load-
available products in which silicones are used as actives or ex-
ed nanoparticles, like targeted drug delivery, controlled re-
cipients. For example, silicones act as antifoams in gastro-
lease, increasing bioavailability of poor water-soluble drugs
enterology, being very effective in anti-acid formulations (6).
(14,15). The nanoparticles used for this purpose, roughly having
The drug release from silicone-containing formulations is
dimensions between 10 and 1,000 nm, may be nanocapsules or
controlled by its diffusion through the silicone network (6,7).
nanospheres. Several characteristics of the particles were recog-
In our previous work, we tested the possibility of using
nized as key parameters for magnified efficacy of nanoparticles
PDMS as a core polymer in nanoparticles obtained by precipi-
for therapeutic applications: particle size, particle shape, surface
tation in the presence of different stabilizers, having a siloxane-
characteristics and release of therapeutics (16).
organic structure (8–10). We have shown that cross-linking of
By combining IMC and PDMS, improved results might be
PDMS may occur in the nanoparticles (9,10), and that improved
obtained in topical applications (due to the substantivity of
stability of the particles is obtained after this step. Taking into
PDMS) or oral administration (due to the low density and
account the properties of polysiloxanes, in particular of PDMS,
antifoam properties of PDMS). These potential benefits
they can be considered an interesting alternative as polymer
prompted a basic investigation on the mutual influence of the
matrix for nanoparticles encapsulating drugs or other active
drug and the matrix, in order to better understand processes like
principles, for oral or topical formulations.
blending, encapsulation or release. In this study, the approach
was to mix PDMS and IMC in different proportions in a common
“Petru Poni” Institute of Macromolecular Chemistry, Aleea Gr.
organic solvent. The obtained blends were investigated by DSC,
Ghica Voda 41A, 700487 Iasi, Romania.
FT-IR, and powder X-ray diffraction and their properties are
Department of Natural and Synthetic Polymers, “Gh. Asachi” Technical
considered the model for nanoparticles obtained thereof. The
3 To whom correspondence should be addressed. (e-mail:
nanoparticles were prepared by re-dissolving the blends in THF
and precipitation in water in the presence of siloxane-based
1530-9932/13/0000-0001/0 # 2013 American Association of Pharmaceutical Scientists
Polydimethylsiloxane–Indomethacin Blends and Nanoparticles
Investigation of PDMS–IMC Blends
Nanoparticles from PDMS–IMC Blends
Anxiety and Panic Disorder What is Anxiety Disorder? Worry and stress in life is an every day occurrence. Anxiety Disorder is when worry is excessive and ongoing, and impedes normal functions. Associated symptoms may include trouble falling asleep, muscle tension, irritability, difficulty concentrating, restlessness, shortness of breath, pounding heartbeat, and fatigue. What is Panic
Verzeichniss der Veröffentlichungen In Vorbereitung Heitbreder M, Joeren N., Dendoerfer A., Depping R., Wagner K.F., Dominiak P.(2005) Hypoxia-Inducible Transcription Factores (HIF): Up-Regulation of HIF-3 alpha by Hypoglycemia. Eingereicht. Veröffentlicht oder “in press” als peer-reviewed Orginalpublikation (IF=impact factor) 36. Iber Th., Weiss M., Wagner K.F., Leidinger W.,